Cytori Therapeutics Inc (NASDAQ:CYTX) Trading Down - Short Interest decreased by -9.22%

The highest price CYTX stock touched in the last 12 month was $2.13 and the lowest price it hit in the same period was $0.28. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has noticeable measure of stock volatility, for this average true range is an exponential moving average (14 trading days) of the True Ranges. Volume was down 95.28% under the stocks average daily volume. The short ratio in the company's stock is documented at 1.47 and the short float is around of 0%. Company shares last traded at $0.56 significantly higher than the 50 day moving average which is $0.39 and significantly lower than the 200 day moving average of $0.81.

Cytori Therapeutics, Inc. has been given an analysts' mean target of 2.17. The trading saw a strength at $129.81, the 52-week high. In this case performance of tends to percentage rate of return for a stock for a given time frame.

Cytori Therapeutics, Inc. (CYTX) performance during the last one year degraded -73 percent, while its year to date (YTD) performance showed a negative trend of -64.25 percent.

These firms have modified their investment in CYTX. Alpha One also assigned media stories about the biotechnology company an impact score of 88 out of 100, indicating that recent press coverage is very likely to have an impact on the stock's share price in the near future. The 50 day moving average went up by +20.4419% and the 200 day average went down $-0.34 or -42.0032%.

Local organizations receive $55K to help victims of domestic violence
Human nature is for us to pretend that it doesn't happen in our community and that it doesn't happen to people we know. The organization has a number of services that are free and confidential to all victims of any crime.

The company's diluted EPS for trailing twelve months was -1.03. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $2.32 million. Next quarter's EPS is estimated at $-0.10 and the next full year EPS is projected to be $-0.43.

EPS growth for the next 5 years is 0 percent. Cytori Therapeutics's revenue was down 53.8% compared to the same quarter past year. The company posted an earnings surprise of 9.5%. The company P/S (price to Sales) ratio is 1.74, P/B (price to Book) ratio is 1.69, while its P/C (price to Cash) ratio stands at 2.4. Maxim Group increased their price objective on Cytori Therapeutics from $6.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, February 15th. A statistical measure of the dispersion of returns (volatility) for CYTX producing salvation in Investors mouth, it has week volatility of 37.68% and for the month booked as 18.33%.

Riley "Downgrades" Cytori Therapeutics (NASDAQ:CYTX) in a research note issued to investors on 7/25/17 to Neutral with price target of $0.

The company last reported its quarterly results on Nov 09 AMC.

Men spinoff Gambit gets a Valentine's Day 2019 release date
Channing Tatum's Gambit movie has had so many false starts, it's nearly surprising the star remains committed to the film. Remy will marry Bella Donna Boudreaux who is his childhood friend and granddaughter of the head assassin.

In terms of Buy, Sell or Hold recommendations, Cytori Therapeutics (NASDAQ:CYTX) has analysts' mean recommendation of 2.3.

Cytori Therapeutics, Inc.'s insider ownership stands at 4.02 percent, while its insider transaction is 0 percent. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0%.

04/06/2015 - Cytori Therapeutics Inc had its "buy" rating reiterated by analysts at Laidlaw.

BioWare vet and Dragon Age director Mike Laidlaw is leaving the company
To anyone who's taken the time to share feedback and experiences, your awesome cosplays and artistic creations: thank you. In his 14 years at the studio, he worked on multiple RPG franchises, including Mass Effect and Jade Empire .

Latest News